154 related articles for article (PubMed ID: 32037733)
1. Outcomes of curative (chemo)radiotherapy for patients with non-p16 positive head and neck squamous cell carcinoma who are borderline for curative treatment.
Xing D; Tiong A; Bressel M; Rischin D; Tran P; Corry J
J Med Imaging Radiat Oncol; 2020 Apr; 64(2):271-278. PubMed ID: 32037733
[TBL] [Abstract][Full Text] [Related]
2. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?
Haehl E; Rühle A; David H; Kalckreuth T; Sprave T; Stoian R; Becker C; Knopf A; Grosu AL; Nicolay NH
Radiat Oncol; 2020 Feb; 15(1):31. PubMed ID: 32019576
[TBL] [Abstract][Full Text] [Related]
4. Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database.
Jensen KH; Vogelius I; Moser CE; Andersen E; Eriksen JG; Johansen J; Farhadi M; Andersen M; Overgaard J; Friborg J
Br J Cancer; 2021 Aug; 125(3):458-464. PubMed ID: 34017084
[TBL] [Abstract][Full Text] [Related]
5. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).
Wintergerst L; Selmansberger M; Maihoefer C; Schüttrumpf L; Walch A; Wilke C; Pitea A; Woischke C; Baumeister P; Kirchner T; Belka C; Ganswindt U; Zitzelsberger H; Unger K; Hess J
Mol Oncol; 2018 Dec; 12(12):2085-2101. PubMed ID: 30259648
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
PLoS One; 2018; 13(7):e0200137. PubMed ID: 29979726
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of head and neck squamous cell carcinoma patients with N3 neck disease treated primarily with chemoradiation versus surgical resection.
Smyth JK; Deal AM; Huang B; Weissler M; Zanation A; Shores C
Laryngoscope; 2011 Sep; 121(9):1881-7. PubMed ID: 21997727
[TBL] [Abstract][Full Text] [Related]
8. Elderly patients affected by head and neck squamous cell carcinoma unfit for standard curative treatment: Is de-intensified, hypofractionated radiotherapy a feasible strategy?
Bonomo P; Desideri I; Loi M; Lo Russo M; Olmetto E; Maragna V; Francolini G; Delli Paoli C; Grassi R; Pezzulla D; Greto D; Meattini I; Livi L
Oral Oncol; 2017 Nov; 74():142-147. PubMed ID: 29103743
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
[TBL] [Abstract][Full Text] [Related]
10. Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.
Rambeau A; Bastit V; Thureau S; Thariat J; Moldovan C; Roge M; Babin E; Gery B; Di Fiore F; Florescu C; Clatot F
Oral Oncol; 2019 Jun; 93():46-51. PubMed ID: 31109695
[TBL] [Abstract][Full Text] [Related]
11. Treatment Package Time in Node-Positive Cutaneous Head and Neck Squamous Cell Carcinoma.
Daniels CP; Bressel M; Corry J; Cole A; Chua MS; Tiong A; Hirshoren N; Dixon B; McDowell L
Pract Radiat Oncol; 2020; 10(1):29-35. PubMed ID: 31606546
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
13. Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
Elbers JBW; Al-Mamgani A; van den Brekel MWM; Jóźwiak K; de Boer JP; Lohuis PJFM; Willems SM; Verheij M; Zuur CL
Otolaryngol Head Neck Surg; 2019 Jun; 160(6):1023-1033. PubMed ID: 30526317
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and selection criteria in the retreatment of head and neck cancers.
May ME; Cash ED; Silverman CL; Redman RA; Perez CA; Wilson LD; Tennant PA; Bumpous JM; Dunlap NE
Oral Oncol; 2019 Jan; 88():85-90. PubMed ID: 30616802
[TBL] [Abstract][Full Text] [Related]
15. Curative-Intent Aggressive Treatment Improves Survival in Elderly Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma and High Comorbidity Index.
Chen JH; Yen YC; Yang HC; Liu SH; Yuan SP; Wu LL; Lee FP; Lin KC; Lai MT; Wu CC; Chen TM; Chang CL; Chow JM; Ding YF; Wu SY
Medicine (Baltimore); 2016 Apr; 95(14):e3268. PubMed ID: 27057882
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
Nathan CO; Hayes DN; Karrison T; Harismendy O; Flores JM; Moore-Medlin T; Vokes EE; Gutkind JS; Neupane P; Mills G; Sargi Z; Seiwert T; Grilley-Olson J; Day T; Gillison M; Wade JL; Feldman L; Jha G; Kozloff M; O'Leary M; Worden FP; Cohen EEW
Clin Cancer Res; 2022 Dec; 28(23):5040-5048. PubMed ID: 36194164
[TBL] [Abstract][Full Text] [Related]
18. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
19. Outcomes for elderly patients 75 years and older treated with curative intent radiotherapy for mucosal squamous cell carcinomas of the head and neck.
Horsley PJ; Perera L; Veness MJ; Stevens MJ; Eade TN; Back M; Brown C; Jayamanne DT
Head Neck; 2020 Jan; 42(1):25-32. PubMed ID: 31593357
[TBL] [Abstract][Full Text] [Related]
20. Individualized treatment of head neck squamous cell carcinoma patients aged 70 or older with radiotherapy alone or associated to cisplatin or cetuximab: impact of weekly radiation dose on loco-regional control.
Belgioia L; Bacigalupo A; Missale F; Vecchio S; Chiola I; Callegari S; Verzanini E; Peretti G; Corvò R
Med Oncol; 2019 Mar; 36(5):42. PubMed ID: 30927146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
